Small Molecule Inhibitors of STAT3 for the Treatment of AML


­Signal transducer and activator of transcription-3 (STAT3) is involved in multiple cancer types and inflammatory diseases. STAT3 is particularly important in leukemic stem cell proliferation and AML progression, which makes it an attractive target for therapeutic inhibition. A team of investigators at the University of Colorado led by Dr. Reigan have created new small molecule inhibitors of STAT3 that may be beneficial in the treatment of multiple cancer types including AML. The inhibitors have shown the ability to decrease leukemic stem cell viability, while not affecting normal hematopoietic stem cells.

Download Summary Document Here:


For Information, Contact:
Mary Tapolsky
University of Colorado
Philip Reigan
Donald Backos
Christopher Matheson
Steffanie Furtek
Disease Areas:
For inquiries, email:     © 2024. All Rights Reserved. Powered by Inteum